External validation of prognostic models: what, why, how, when and where?
Chava L. Ramspek(Parnassia Groep), Merel van Diepen(Leiden University Medical Center), Kitty J. Jager(Amsterdam University Medical Centers), Carmine Zoccali(Biogem), Friedo W. Dekker(Leiden University Medical Center)
Cited by 808
Related Papers
Obesity and Kidney Disease: Hidden Consequences of the Epidemic
|American Journal of Nephrology|2017|2.2k
Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study
|The Lancet|2001|1.1k
Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria
|The Lancet|1999|909
A single number for advocacy and communication—worldwide more than 850 million individuals have kidney diseases
|Kidney International|2019|886
An introduction to inverse probability of treatment weighting in observational research
|Clinical Kidney Journal|2021|877